Exploring methylene blue as an effective alternative to radiotracer for sentinel lymph node biopsy in early breast cancer in resource-limited settings

Bhavin P. Vadodariya; Murtuza I. Laxmidhar; Anagha Zope; Shakuntala V. Shah

doi:10.18203/2349-2902.isj20243229

Authors

Bhavin P. Vadodariya Department of Surgical Oncology, Apollo Hospital, Ahmedabad, Gujarat, India
Murtuza I. Laxmidhar Department of Surgical Oncology, Apollo Hospital, Ahmedabad, Gujarat, India
Anagha Zope Department of Surgical Oncology, Apollo Hospital, Ahmedabad, Gujarat, India
Shakuntala V. Shah Department of Surgical Oncology, Apollo Hospital, Ahmedabad, Gujarat, India

DOI:

https://doi.org/10.18203/2349-2902.isj20243229

Keywords:

Methylene blue, Sentinel lymph node biopsy, Early breast cancer, Radiotracer alternative, Resource-limited settings, Breast cancer surgery

Abstract

Background: Sentinel lymph node biopsy is the recommended approach in the evaluation of axilla during breast cancer surgery. This study evaluated the results of patients who underwent methylene blue sentinel lymph node biopsy.

Methods: The study included 35 female patients with T1, T2 and T3 tumours. 5 ml of 1% methylene blue was injected into the periareolar region. The axillary sentinel lymph node was found and removed, and axillary dissection was performed. The sentinel lymph node and axillary dissection specimen were histopathologically examined, and the results were compared.

Results: The sentinel lymph node was found in 33 (90%) patients. There were no complications associated with the use of methylene blue dye. Methylene blue-stained sentinel nodes were histologically negative for malignancy in 42% and positive in 58% of patients. Corresponding to sentinel nodes, the final axillary staging was negative in 60% and positive in 40% of patients. On diagnostic accuracy parameters, the sensitivity of the methylene blue method in early breast cancer (cT1-3N0M0) patients was 90.47%, and the specificity was 100%. The PPV of the technique under study was found to be 100% and NPV was 85.71%. The accuracy rate was 93%, and the false negative rate was identified as 9.5%.

Conclusions: Sentinel lymph node biopsy by methylene blue is a method that can be applied with high accuracy. Methylene blue can be considered as an alternative to radio colloid dye in sentinel lymph node biopsy in a limited resource setting.

Metrics

Metrics Loading ...

References

World Health Organization. Cancer. 2021. Available at: https://www.who.int/news-room/fact-sheets/ detail/cancer. Accessed on 06 August 2023.

The Global Cancer Observatory. India Globocan 2020 [Fact Sheet]. International Agency for Research on Cancer. 2021. https://gco.iarc.fr/today/data/ factsheets/populations/356-india-fact-sheets.pdf. Accessed on 06 August 2023.

Van Maaren M, de Munck L, de Bock G, Jobsen J, van Dalen T, Linn S, et al. 10-year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study. Lancet Oncol. 2016;17(8):1158-70.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomised study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;34716:1227-32.

Ecanow JS, Abe H, Newstead GM, Ecanow DB, Jeske JM. Axillary staging of breast cancer: what the radiologist should know. Radiographics. 2013;33(6):1589-612.

Manca G, Rubello D, Tardelli E, Giammarile F, Mazzarri S, Boni G, et al. Sentinel lymph node biopsy in breast cancer: indications, contraindications, and controversies. Clin Nucl Med. 2016;41(2):126-33.

Jatoi I, Benson JR, Toi M. De-escalation of axillary surgery in early breast cancer. Lancet Oncol. 2016;17(10):e430-41.

Charalampoudis P, Markopoulos C, Kovacs T. Controversies and recommendations regarding sentinel lymph node biopsy in primary breast cancer: a comprehensive review of current data. Eur J Surg Oncol. 2018;44(1):5-14.

Manca G, Tardelli E, Rubello D, Gennaro M, Marzola MC, Cook GJ, et al. Sentinel lymph node biopsy in breast cancer: a technical and clinical appraisal. Nucl Med Commun. 2016;37(6):570-6.

Niebling MG, Pleijhuis RG, Bastiaannet E, Brouwers AH, van Dam GM, Hoekstra HJ. A systematic review and meta-analyses of sentinel lymph node identification in breast cancer and melanoma, a plea for tracer mapping. Eur J Surg Oncol. 2016;42(4):466-73.

Zengel B, Yararbas U, Sirinocak A, Ozkok G, Denecli AG, Postaci H, et al. Sentinel lymph node biopsy in breast cancer: review on various methodological approaches. Tumori. 2013;99(2):149-53.

Li J, Chen X, Qi M, Li Y, Metze K. Sentinel lymph node biopsy mapped with methylene blue dye alone in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2018;13(9):e0204364.

Sugie T, Ikeda T, Kawaguchi A, Shimizu A, Toi M. Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis. Int J Clin Oncol. 2017;22(1):11-7.

Guo J, Yang H, Wang S, Cao Y, Liu M, Xie F, et al. Comparison of sentinel lymph node biopsy guided by indocyanine green, blue dye, and their combination in breast cancer patients: a prospective cohort study. World J Surg Oncol. 2017;15(1):196.

Somashekhar SP, Zaveri Shabber S, Udupa Venkatesh K, Venkatachala K, Parameshwaran, Vasan Thirumalai MM. Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid - a single institution Indian experience. Indian J Surg. 2008;70(3):111-9.

Brahma B, Putri RI, Karsono R, Andinata B, Gautama W, Sari L, et al. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital. World J Surg Oncol. 2017;15(1):41.

Nandu VV, Chaudhari MS. Efficacy of Sentinel Lymph Node Biopsy in Detecting Axillary Metastasis in Breast Cancer Using Methylene Blue. Indian J Surg Oncol. 2017;8(2):109-12.

Straver ME, Meijnen P, van Tienhoven G, van de Velde CJ, Mansel RE, Bogaerts J, et alJ. Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial. Ann Surg Oncol. 2010;17(7):1854-61.

Shah-Khan M, Boughey JC. Evolution of axillary nodal staging in breast cancer clinical implications of the ACOSOG Z0011 trial. Cancer Control. 2012;19(4):267-76.